Hiroki Kawashima

Prof. Dr. Hiroki Kawashima

Department of Gastroenterology and Hepatology, Nagoya University, Nagoya, Aichi, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2003 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
YHYoshiki Hirooka
Yoshiki Hirooka
HGHidemi Goto
Hidemi Goto
AIAkihiro Itoh
Akihiro Itoh
SHSenju Hashimoto
Senju Hashimoto
KNKatsushi Niwa
Katsushi Niwa
HKHiroki Kawashima
Hiroki Kawashima

25 May 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YHYoshiki Hirooka
Yoshiki Hirooka
Hideki KasuyaHideki Kasuya
Hideki Kasuya
Takuya IshikawaTakuya Ishikawa
Takuya Ishikawa
HKHiroki Kawashima
Hiroki Kawashima
EOEizaburo Ohno
Eizaburo Ohno
HGHidemi Goto
Hidemi Goto
Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study. This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment. Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013.

1 December 2016 in American Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
MSMasaaki Shimatani
Masaaki Shimatani
HHHisashi Hatanaka
Hisashi Hatanaka
HKHirofumi Kogure
Hirofumi Kogure
KTKoichiro Tsutsumi
Koichiro Tsutsumi
HKHiroki Kawashima
Hiroki Kawashima
KSKentaro Sugano
Kentaro Sugano
To evaluate the utility and safety of a short-type double-balloon endoscope (DBE) in the treatment of biliary disease in patients with surgically altered gastrointestinal (GI) anatomy. This study was conducted as a multicenter, single-arm, prospective trial at five tertiary academic care centers and three community-based hospitals in Japan. Consecutive patients with biliary disease with altered GI anatomy were prospectively included in this study. A total of 311 patients underwent double-balloon endoscopic retrograde cholangiography (ERC). The success rate of reaching the target site, the primary end point, was 97.7% (95% confidence interval (CI): 95.4–99.1). The success rate of biliary cannulation and contrast injection of the targeted duct, the secondary end point, was 96.4% (95% CI: 93.6–98.2), and the therapeutic success rate was 97.9% (95% CI: 95.4–99.2). Adverse events occurred in 33 patients (10.6%, 95% CI: 7.1–14.0) and were managed conservatively in all patients with the exception of 1 in whom a perforation developed, requiring emergency surgery. ERC using a short-type DBE resulted in an excellent therapeutic success rate and a low rate of adverse events. This treatment can be a first-line treatment for biliary disease in patients with surgically altered GI anatomy.

1 November 1997 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
HYHiroaki Yoshikane
Hiroaki Yoshikane
HHHitoshi Hidano
Hitoshi Hidano
ASAkira Sakakibara
Akira Sakakibara
TATadao Ayakawa
Tadao Ayakawa
SMSumito Mori
Sumito Mori
YNYasumasa Niwa
Yasumasa Niwa

1 January 2013 in Annals of Surgery
Verified
Journal Article
Closed access
HKHiroki Kawashima
Hiroki Kawashima
AIAkihiro Itoh
Akihiro Itoh
EOEizaburo Ohno
Eizaburo Ohno
YIYuya Itoh
Yuya Itoh
TETomoki Ebata
Tomoki Ebata
YHYoshiki Hirooka
Yoshiki Hirooka
To assess the clinical benefits of preoperative endoscopic nasobiliary drainage (ENBD) in patients with perihilar cholangiocarcinoma. The advantages of ENBD have been previously reported. However, no studies to date have examined a large number of patients, including those with Bismuth-Corlette (B-C) type III to IV tumors. In addition, sufficient data on the risk factors associated with ENBD complications are not available. This study involved 164 consecutive patients with suspected perihilar cholangiocarcinoma (128 patients with B-C type III–IV tumors) who had undergone unilateral ENBD between January 2007 and December 2010. The success and efficacy of this procedure and the risk factors for post-ENBD cholangitis and pancreatitis were retrospectively evaluated. The ENBD procedure was successful in 153 (93.3%) of the 164 patients. Of these 164 patients, 65 had serum total bilirubin (TB) levels of 2.0 mg/dL or more before the drainage. The first unilateral ENBD was successfully performed in 60 of the 65 patients, and the TB level decreased to less than 2.0 mg/dL after ENBD in 50 of these 60 patients (83.3%). The significant predictive factors for ENBD efficacy included the pre-ENBD TB level (P = 0.032; 95% confidence interval [CI], 1.01–1.23) and post-ENBD cholangitis (P = 0.012; 95% CI, 1.61–43.2). Post-ENBD cholangitis occurred in 47 (28.8%) of the 163 patients, and a previous endoscopic sphincterotomy (EST) was found to be a significant risk factor for post-ENBD cholangitis (P = 0.008; 95% CI, 1.30–5.46). Post-ENBD pancreatitis occurred in 33 (20.1%) of the 164 patients (26 grade 1 patients, 4 grade 2 patients, and 3 grade 3 patients). The significant risk factors included undergoing pancreatography (P < 0.001; 95% CI, 2.44–31.1) and the absence of previous EBS or ENBD (P < 0.001; 95% CI, 3.03–29.2). Unilateral ENBD of the future remnant lobe(s) exhibited a high success rate, suggesting that it is an effective and suitable preoperative drainage method for perihilar cholangiocarcinoma even in patients with B-C type III to IV tumors. To reduce the postprocedural complications, ENBD should be performed without EST or pancreatography.

1 May 2010 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
TITakuya Ishikawa
Takuya Ishikawa
AIAkihiro Itoh
Akihiro Itoh
HKHiroki Kawashima
Hiroki Kawashima
EOEizaburo Ohno
Eizaburo Ohno
HMHiroshi Matsubara
Hiroshi Matsubara
YHYoshiki Hirooka
Yoshiki Hirooka